Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Casein kinase II, alpha chain | 0.0134 | 0.1447 | 0.4967 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0134 | 0.1447 | 1 |
Loa Loa (eye worm) | CMGC/CK2 protein kinase | 0.0134 | 0.1447 | 0.4967 |
Schistosoma mansoni | hypothetical protein | 0.0037 | 0.024 | 0.166 |
Entamoeba histolytica | casein kinase, putative | 0.0134 | 0.1447 | 1 |
Trypanosoma brucei | Casein kinase II | 0.0134 | 0.1447 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0023 | 0.0074 | 0.0254 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0023 | 0.0074 | 0.0074 |
Brugia malayi | aryl hydrocarbon receptor nuclear translocator protein, putative | 0.0023 | 0.0074 | 0.0254 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0134 | 0.1447 | 1 |
Brugia malayi | hypothetical protein | 0.0037 | 0.024 | 0.0824 |
Toxoplasma gondii | CMGC kinase, CK2 family | 0.0134 | 0.1447 | 0.5 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0023 | 0.0074 | 0.0511 |
Schistosoma mansoni | protein kinase | 0.0134 | 0.1447 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0023 | 0.0074 | 0.0511 |
Plasmodium vivax | unspecified product | 0.0134 | 0.1447 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0037 | 0.024 | 0.166 |
Trypanosoma cruzi | casein kinase II, putative | 0.0134 | 0.1447 | 0.5 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0023 | 0.0074 | 0.0511 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0134 | 0.1447 | 1 |
Mycobacterium leprae | Possible transporter protein | 0.0023 | 0.0074 | 0.5 |
Giardia lamblia | Kinase, CMGC CK2 | 0.0134 | 0.1447 | 0.5 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0023 | 0.0074 | 0.0511 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0023 | 0.0074 | 0.0511 |
Brugia malayi | Voltage-gated potassium channel, EAG (KCNH1)-related. C. elegans egl-2 ortholog | 0.0023 | 0.0074 | 0.0254 |
Onchocerca volvulus | 0.0232 | 0.2668 | 0.5 | |
Echinococcus multilocularis | voltage gated potassium channel | 0.0023 | 0.0074 | 0.0074 |
Leishmania major | casein kinase II, putative | 0.0134 | 0.1447 | 0.5 |
Schistosoma mansoni | 60S ribosomal protein L21 | 0.0023 | 0.0074 | 0.0511 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0252 | 0.2913 | 1 |
Plasmodium falciparum | casein kinase 2, alpha subunit | 0.0134 | 0.1447 | 0.5 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0023 | 0.0074 | 0.0511 |
Echinococcus granulosus | voltage gated potassium channel | 0.0023 | 0.0074 | 0.0511 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0134 | 0.1447 | 1 |
Plasmodium vivax | casein kinase 2, alpha subunit, putative | 0.0134 | 0.1447 | 0.5 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0023 | 0.0074 | 0.0511 |
Brugia malayi | MH2 domain containing protein | 0.0252 | 0.2913 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0037 | 0.024 | 0.024 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0252 | 0.2913 | 1 |
Echinococcus granulosus | casein kinase ii subunit alpha | 0.0134 | 0.1447 | 1 |
Loa Loa (eye worm) | CAMK/CAMKL/PASK protein kinase | 0.0232 | 0.2668 | 0.9158 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0134 | 0.1447 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0134 | 0.1447 | 1 |
Echinococcus granulosus | single minded 2 | 0.0023 | 0.0074 | 0.0511 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0037 | 0.024 | 0.166 |
Echinococcus multilocularis | casein kinase ii subunit alpha | 0.0134 | 0.1447 | 0.1447 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0134 | 0.1447 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0134 | 0.1447 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.